Glycopeptide susceptibility profiles of nosocomial multiresistant Staphylococcus haemolyticus isolates
- PMID: 11810575
- DOI: 10.1007/s101560100026
Glycopeptide susceptibility profiles of nosocomial multiresistant Staphylococcus haemolyticus isolates
Abstract
We investigated 48 Staphylococcus haemolyticus isolates from patients and medical staff in terms of susceptibility to and in-vitro selection for vancomycin and teicoplanin in regard to their antibiotypes. On comparison of multiresistant S. haemolyticus isolates with non-multiresistant isolates, the geometric mean minimum inhibitory concentration (MIC) of vancomycin for multiresistant S. haemolyticus was 2.9 microg/ml, and that of teicoplanin was 18.0 microg/ml, both of which values were significantly greater than the corresponding mean MICs of vancomycin (2.0 microg/ml) and teicoplanin (4.7 microg/ml) for nonmultiresistant isolates. After agar selection, the mean of the highest teicoplanin concentration of selected plates for multiresistant S. haemolyticus was 97.1 microg/ml, which was significantly higher than that for nonmultiresistant isolates (57.8 microg/ml). However, the means' of the highest vancomycin concentrations after agar selection for multiresistant and nonmulti-resistant isolates were the same, at 7.4 microg/ml, with no colonies capable of growing in 32 microg/ml of vancomycin. There was no significant difference in glycopeptide susceptibility between oxacillin-resistant and oxacillin-susceptible isolates among nonmultiresistant S. haemolyticus. The geometric mean MICs of vancomycin for oxacillin-resistant and oxacillin-susceptible isolates were 2.1 microg/ml and 1.6 microg/ml, and those of teicoplanin were 4.4 microg/ml and 5.6 microg/ml, while the means of the highest concentrations of the selected plates of vancomycin were 8.6 microg/ml and 3.3 microg/ml, and those of teicoplanin were 52.8 microg/ml and 74.7 microg/ml, respectively. Multiresistant isolates showed significantly greater mean MICs of vancomycin and teicoplanin and higher teicoplanin concentration of the selected plates than nonmultiresistant isolates, irrespective of oxacillin resistance. These results indicate that methicillin resistance may not be related to reduced susceptibility to glycopeptide in S. haemolyticus, and that a multiresistant profile is associated more with a decreasing susceptibility to glycopeptides then with resistance to oxacillin. In this study, antibiotypes showed good concordance with pulsed-field gel electrophoresis typing results, with a sufficiently high discriminatory ability index, of 0.912. We consider that primary screening with antimicrobial susceptibility testing and antibiotyping, with attention to the multiresistant profile, would be useful for monitoring nosocomial S. haemolyticus colonization and infection.
Similar articles
-
Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides.Diagn Microbiol Infect Dis. 1999 Jul;34(3):185-91. doi: 10.1016/s0732-8893(99)00034-6. Diagn Microbiol Infect Dis. 1999. PMID: 10403098
-
[Activity of vancomycin, teicoplanin and linezolid in methicillin resistant coagulase-negative Staphylococci isolates from paediatric blood cultures].Rev Esp Quimioter. 2012 Mar;25(1):25-30. Rev Esp Quimioter. 2012. PMID: 22488538 Spanish.
-
Susceptibility Profile of Staphylococcus epidermidis and Staphylococcus haemolyticus Isolated from Blood Cultures to Vancomycin and Novel Antimicrobial Drugs over a Period of 12 Years.Microb Drug Resist. 2016 Jun;22(4):283-93. doi: 10.1089/mdr.2015.0064. Epub 2015 Dec 1. Microb Drug Resist. 2016. PMID: 26623676
-
Glycopeptide resistance in coagulase-negative staphylococci.Eur J Clin Microbiol Infect Dis. 2000 Jun;19(6):403-17. doi: 10.1007/s100960000299. Eur J Clin Microbiol Infect Dis. 2000. PMID: 10947214 Review.
-
Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides.Ther Drug Monit. 1998 Oct;20(5):473-7. doi: 10.1097/00007691-199810000-00005. Ther Drug Monit. 1998. PMID: 9780121 Review.
Cited by
-
Characterization of coagulase-negative staphylococcal isolates from blood with reduced susceptibility to glycopeptides and therapeutic options.BMC Infect Dis. 2009 Jun 4;9:83. doi: 10.1186/1471-2334-9-83. BMC Infect Dis. 2009. PMID: 19497104 Free PMC article.
-
The Fusaric Acid Derivative qy17 Inhibits Staphylococcus haemolyticus by Disrupting Biofilm Formation and the Stress Response via Altered Gene Expression.Front Microbiol. 2022 Mar 14;13:822148. doi: 10.3389/fmicb.2022.822148. eCollection 2022. Front Microbiol. 2022. PMID: 35369527 Free PMC article.
-
In Vitro Activity of Rifampicin Combined with Daptomycin or Tigecycline on Staphylococcus haemolyticus Biofilms.Curr Microbiol. 2015 Aug;71(2):184-9. doi: 10.1007/s00284-015-0821-y. Epub 2015 Apr 18. Curr Microbiol. 2015. PMID: 25894996 Free PMC article.
-
Significance of methicillin-teicoplanin resistant Staphylococcus haemolyticus in bloodstream infections in patients of the Semmelweis University hospitals in Hungary.Eur J Clin Microbiol Infect Dis. 2011 May;30(5):691-9. doi: 10.1007/s10096-010-1142-5. Epub 2011 Jan 11. Eur J Clin Microbiol Infect Dis. 2011. PMID: 21222010
-
Sphygmomanometers and thermometers as potential fomites of Staphylococcus haemolyticus: biofilm formation in the presence of antibiotics.Mem Inst Oswaldo Cruz. 2017 Mar;112(3):188-195. doi: 10.1590/0074-02760160381. Epub 2017 Feb 16. Mem Inst Oswaldo Cruz. 2017. PMID: 28225903 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical